LMNB1 Gene Leukodystrophy Demyelinating Adult-Onset Autosomal Dominant Genetic Test
Test Name: LMNB1 Gene Leukodystrophy Demyelinating Adult-Onset Autosomal Dominant Genetic Test
- Components: NGS Technology
- Price: 4400.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Test Type: Neurological Disorders
- Doctor: Neurologist
- Test Department: Genetics
- Pre Test Information: Clinical History of Patient who is going for LMNB1 Gene Leukodystrophy Demyelinating Adult-Onset Autosomal Dominant NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with LMNB1 Gene Leukodystrophy Demyelinating Adult-Onset Autosomal Dominant.
Test Details
The LMNB1 gene is associated with a type of leukodystrophy called adult-onset demyelinating leukodystrophy. Leukodystrophies are a group of genetic disorders that affect the white matter of the brain, leading to a loss of myelin, the protective covering of nerve fibers. In the case of LMNB1-related leukodystrophy, the condition typically manifests in adulthood, usually between the ages of 20 and 50. It is inherited in an autosomal dominant manner, meaning that an affected individual has a 50% chance of passing on the gene mutation to each of their children.
NGS (Next-Generation Sequencing) genetic testing is a technique used to analyze multiple genes simultaneously, allowing for a more comprehensive evaluation of genetic variations. In the context of LMNB1-related leukodystrophy, NGS genetic testing can identify specific mutations or variations in the LMNB1 gene that may be responsible for the condition. By undergoing NGS genetic testing for LMNB1-related leukodystrophy, individuals and their families can gain a better understanding of the genetic basis of the condition, which can inform medical management and genetic counseling decisions.
| Test Name | LMNB1 Gene Leukodystrophy demyelinating adult-onset autosomal dominant Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for LMNB1 Gene Leukodystrophy demyelinating adult-onset, autosomal dominant NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with LMNB1 Gene Leukodystrophy demyelinating adult-onset, autosomal dominant |
| Test Details |
The LMNB1 gene is associated with a type of leukodystrophy called adult-onset demyelinating leukodystrophy. Leukodystrophies are a group of genetic disorders that affect the white matter of the brain, leading to a loss of myelin, the protective covering of nerve fibers. In the case of LMNB1-related leukodystrophy, the condition typically manifests in adulthood, usually between the ages of 20 and 50. It is inherited in an autosomal dominant manner, meaning that an affected individual has a 50% chance of passing on the gene mutation to each of their children. NGS (Next-Generation Sequencing) genetic testing is a technique used to analyze multiple genes simultaneously, allowing for a more comprehensive evaluation of genetic variations. In the context of LMNB1-related leukodystrophy, NGS genetic testing can identify specific mutations or variations in the LMNB1 gene that may be responsible for the condition. By undergoing NGS genetic testing for LMNB1-related leukodystrophy, individuals and their families can gain a better understanding of the genetic basis of the condition, which can inform medical management and genetic counseling decisions. |

